Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $76 from $74 and keeps an Outperform rating on the shares. Mirum raised its 2025 revenue guidance on a strong Q1 beat ahead of an “interesting” update on volixibat, the analyst tells investors in a research note. The firm continues to like the opportunity in both primary sclerosing cholangitis and primary biliary cholangitis given the high unmet need and Mirum’s competitive positioning with the FDA signing off on pruritus as a registrational endpoint for both indications.